Special Effects of Antibiotic Treatment on the Appearance of Intestinal Cytochrome

Muhammad Fiaz, Hafiz Zain-ul-Abdeen, Fahad Raza Hashmi


Expression of metabolic enzymes Cytochrome P450 (CYP) is highly affected by drugs, diseases, age and gender. The Intestinal microflora has been suggested to play a role in regulating CYP expression and antibiotic treatments would lead to changes in level and composition of microbiota in mouse gut. This paper aims to analyze CYP expression changes in the liver and small intestine resulted from the reduction of intestinal microflora by antibiotics. Impacts on bile acid signaling were also analyzed for a better comprehension of the mechanisms involved in this modulation. Female C57BL/6J mice (9- to 13-week old) were treated with ampicillin (AMP) or vehicle for 3 or 7 days. Analysis of mRNA expression level indicated decreased expression of CYP2B10 in liver and intestine of mice treated for 3 days. In 7 days of AMP treatment, CYP3A11 mRNA levels were decreased in liver and increased in the intestine of mice. The AMP treatment reduced the population of lithocholic acid-producing bacterial strains and led to decreased expression of fibroblast growth factor 15 (FGF15) and increased expression of apical sodium-dependent bile acid transporter (ASBT). Enlarged gallbladders and the increased levels of CYP7A1 mRNA suggested an increase of bile acid synthesis and bile secretion. This paper indicates that changes in the microflora can modulate CYP expression in mouse liver and intestine. A full understanding of the role of gut microflora in xenobiotic metabolism is desirable in order to predict drug-drug interactions, drug-diet interactions, and individual pharmacokinetic differences.



Liver, intestine cytochrome p450, antibiotics

Full Text:



Akiyoshi, T. et al., 1986. Cholesterol gallstones in alloxan-diabetic mice. Journal of Lipid Research, 27(20), pp.915–924.

Alterman, M. et al., 1993. Effects of aging and long-term caloric restriction on hepatic microsomal monooxygenases in female FISCHER 344 rats: alterations in basal cytochrome P-450 catalytic activities. Age, 16, pp.1–8.

Cazzola, M., Blasi, F. & Ewig, S., 2004. European Respiratory Monograph 28: Antibiotics and

the Lung:, European Respiratory Society Journals.

Chang, G.W.M. & Kam, P.C.A., 1999. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia, 54(1), pp.42–50.

Chen, J. & Raymond, K., 2006. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Annals of clinical microbiology and antimicrobials, 5, p.3.

Chen, J., Zhao, K.-N. & Chen, C., 2014. The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. Annals of translational medicine, 2(1), p.7.

Claus, S.P. et al., 2011. Colonization-Induced Host-Gut Microbial Metabolic Interaction. mBio, 2(2), pp.e00271-10-e00271-10.

Correia, M.A., Sinclair, P.R. & Matteis, F. De, 2011. Cytochrome P450 regulation: the interplay between its heme and apoprotein moieities in synthesis, assembly, repair and disposal. Drug Metab Rev, 43(1), pp.1–26.

Coyle, D. & Dull, R.O., 2015. CYP2B: 2B or Not 2B? In C. Marcucci et al., eds. A Case

Approach to Perioperative Drug-Drug Interactions. New York, NY: Springer New York,pp. 45–47.

Giguere, S. et al., 2013. Antimicrobial therapy in veterinary medicine, 5th edition fifth., Ames Iowa, USA: John Wiley & Sons.

Hofmann, A.F., 2015. The continuing importance of bile acids in liver and intestinal disease.

Archives of internal medicine, 159(22), pp.2647–2658.

Hrycay, E.G. & Bandiera, S.M., 2015. Monooxygenase, Peroxidase and Peroxygenase Properties and Mechanisms of Cytochrome, Springer International Publishing.

Ioannides, C. & of Chemistry (Great Britain), R.S., 2008. Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and Other Xenobiotics, RSC Pub.

Ishii, M. et al., 2012. Efects of Intestinal Flora on the Expression of Cytochrome P450 3A in the Liver. The Pharmaceutical Society of Japan, 132(3), pp.301–310.

Kamataki, T. et al., 1985. Age-related alteration in the activities of drug-metabolizing enzymes and contents of sex-specific forms of cytochrome P-450 in liver microsomes from male and female rats. The Journal of Pharmacology and Experimental Therapeutics, 233(1), pp.222– 8.

Kawauchi, S., Nakamura, T., Miki, I., et al., 2014. Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations. Journal of pharmacological sciences, 124(2), pp.180–91.

Kawauchi, S., Nakamura, T., Yasui, H., et al., 2014. Intestinal and hepatic expression of cytochrome P450s and mdr1a in rats with indomethacin-induced small intestinal ulcers. International Journal of Medical Sciences, 11(12), pp.1208–1217.

Klaassen, C.D. & Cui, J.Y., 2015. Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids. Drug metabolism and disposition: the biological fate of chemicals, 43(10), pp.1505–21.

Kraemer, J. et al., 1982. Altered. pediatrics, 69(4).

Kuno, T. et al., 2016. Effect of Intestinal Flora on Protein Expression of Drug-Metabolizing Enzymes and Transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice. Molecular Pharmaceutics, 13(8), pp.2691–2701.

Lewis, D.F.V., Ito, Y. & Goldfarb, P.S., 2005. Cytochrome P450 structures and their substrate interactions. Drug Development Research, 66(1), pp.19–24.

Liu, C. et al., 2003. Rapid identification of the species of the Bacteroides fragilis group by multiplex PCR assays using group- and species-specific primers. FEMS Microbiology Letters, 222(1), pp.9–16.

Mann, H.J., 2006. Drug-Associated Disease: Cytochrome P450 Interactions. Critical Care Clinics, 22(2), pp.329–345.

Miyata, M. et al., 2011. Enterobacteria modulate intestinal bile acid transport and homeostasis through apical sodium-dependent bile acid transporter (SLC10A2) expression. The Journal of pharmacology and experimental therapeutics, 336(1), pp.188–96.

Morgan, E., 2009. Impact of Infectious and Inflammatory Disease on Cytochrome P450– Mediated Drug Metabolism and Pharmacokinetics. Clinical Pharmacology & Therapeutics, 85(4), pp.434–438.

Neve, E.P. & Ingelman-Sundberg, M., 2010. Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. Current opinion in drug discovery & development, 13(1), pp.78–85.

Niwa, T. et al., 2016. Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. , 41(1), pp.143–146.

Paine, M.F. et al., 2006. The human intestinal cytochrome P450 “pie.” Drug metabolism and disposition, 34(5), pp.880–6.

Renaud, H.J. et al., 2011. Tissue distribution and gender-divergent expression of 78 cytochrome p450 mRNAs in mice. Toxicological Sciences, 124(2), pp.261–277.

Samsel, A. & Seneff, S., 2013. Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases. Entropy, 15(4), pp.1416–1463.

Schmucker, D.L., 2001. Liver function and phase I drug metabolism in the elderly: a paradox.

Drugs & Aging, 18(11), pp.837–851.

Selwyn, F.P., Cui, J.Y. & Klaassen, C.D., 2015. Special section on drug metabolism and the microbiome RNA-seq quantification of hepatic drug processing genes in germ-free mice. Drug Metabolism and Disposition, 43(10), pp.1572–1580.

Thelen, K. & Dressman, J.B., 2009. Cytochrome P450-mediated metabolism in the human gut wall. Journal of Pharmacy and Pharmacology, 61(5), pp.541–558.

Thummel, K.E., 2007. Gut instincts: CYP3A4 and intestinal drug metabolism. , 117(11), pp.10– 13.

Toda, T., Saito, N., et al., 2009. Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica, 39(4), pp.323–334.

Vaiserman, A.M., Koliada, A.K. & Marotta, F., 2017. Gut microbiota: A player in aging and a target for anti-aging intervention. Ageing Research Reviews, 35, pp.36–45.

Wang, R.F., Cao, W.W. & Cerniglia, C.E., 1996. PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples. Applied and environmental microbiology, 62(4), pp.1242–7.

Wynne, H.A. et al., 1988. The effect of age upon the affinity of microsomal mono-oxygenase enzymes for substrate in human liver. age and ageing, 17, pp.401–405.

Xie, H.-J. et al., 2003. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone marrow transplantation, 31(3), pp.197– 203.

Zanger, U.M. & Schwab, M., 2013. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and Therapeutics, 138(1), pp.103–141.

Zhang, Q., Dunbar, D. & Kaminsky, L.S., 2003. Characterization of mouse small intestinal cytochrome P450 expression. Drug metabolism and disposition, 31(11), pp.1346–1351.

Zhang, X.J. et al., 2015. Pyrene is a novel constitutive androstane receptor (CAR) activator and causes hepatotoxicity by CAR. Toxicological Sciences, 147(2), pp.436–445.

Zhou, S.F., Liu, J.P. & Chowbay, B., 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev, 41(2), pp.89–295.

Zhu, Y. et al., 2014. Regulation of intestinal cytochrome P450 expression by hepatic cytochrome

P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure. Molecular pharmacology, 85(1), pp.139–47.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.